Navigation Links
Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders
Date:12/13/2010

LA JOLLA, Calif., Dec. 13, 2010 /PRNewswire/ -- Anaphore Inc. today announced that the company has entered into a partnership with Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) for the research, development and commercialization of novel protein therapies for autoimmune disease.

The partnership will be based on Anaphore's proprietary platform technology, which generates novel trivalent proteins called Atrimers(TM) with binding domains that can be programmed to bind to and activate or inhibit nearly any target of interest. The agreement stipulates an initial target for the research program. Tanabe Research Laboratories U.S.A., Inc. (TRL), a San Diego-based subsidiary of Mitsubishi Tanabe Pharma, has the option to nominate two additional autoimmune targets against which Anaphore would develop potential protein therapeutics. Under the terms of the agreement, Mitsubishi Tanabe Pharma will make an upfront payment of $5 million for an initial target and contribute research funds. In addition, Anaphore will receive milestone payments totaling $110 million and tiered royalties on sales, provided the nominated molecule achieves full commercialization. Financial terms are substantially similar in the event TRL nominates two additional targets.

"Our work with Anaphore will further strengthen our initiative to bring next-generation biologics to physicians and their patients," said Minoru Muramatsu, Ph.D., Executive Officer, Research, Mitsubishi Tanabe Pharma. "We will initiate the research program immediately to expand on the promising work Anaphore has already done with Atrimer technology."

The partnership will focus on strategies to develop superior biologic therapies for autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. TRL and Anaphore will commence the research and development alliance immediately.

"This agreement exemplifies Anaphore's plan to form partnerships while exploring the potential of Atrimers to improve therapy in a wide range of diseases," said Katherine Bowdish, Ph.D., Anaphore's Chief Executive Officer. "In Mitsubishi Tanabe Pharma, we have a partner with a record of success in the biologics market and a commitment to advancing a new class of protein therapeutics for immune-system disorders."

Initial research activities will be conducted by TRL and Anaphore. Mitsubishi Tanabe Pharma will be responsible for late stage development and worldwide commercialization following the selection of lead candidates.

About Mitsubishi TanabePharma and Tanabe Research Laboratories U.S.A.,Inc. (TRL)Mitsubishi Tanabe Pharma Corporation is a research-driven pharmaceutical company based in Japan, specializing in research, development and marketing of globally competitive pharmaceutical products focused on the immune and inflammatory field, and the metabolism and cardiovascular field.  Mitsubishi Tanabe Pharma contributes to the healthier lives of people around the world through the creation of pharmaceuticals.

http://www.mt-pharma.co.jp/e

TRL is an independent subsidiary of Mitsubishi Tanabe Pharma Corporation whose role is to discover and develop potential biological drug candidates for therapy in autoimmune diseases.

Currently, TRL's efforts will be directed towards antibody and antibody related research to target specific immune cells and soluble factors, as well as investigating new methods for modulating immune cell functions. TRL will establish collaborative relationships with other companies and academic research organizations to further its goals of identifying lead preclinical compounds for further development and to consolidate its presence in immunology.  

http://www.trlusa.com/

About AnaphoreAnaphore is developing a new class of protein pharmaceuticals to address significant unmet medical needs for patients with serious diseases. The company's Atrimer technology platform originates in tetranectin, a human plasma protein of trivalent structure. Each of the three binding domains comprises five distinct amino-acid loops that can be programmed to bind potently and specifically to virtually any target of interest.  Atrimers potentially offer biological, manufacturing, and commercial advantages over currently marketed therapies. Atrimer protein therapeutics are protected by intellectual property including multiple patent families.

Anaphore's initial therapeutic focus is immunology and oncology. In collaboration with select partners, Anaphore is committed to realizing the full promise of Atrimers against targets in a wide range of therapeutic areas, including rare diseases.

Since its founding in 2008, Anaphore has raised $38 million in financing from top-tier biotechnology investors 5AM Ventures, Versant Ventures, Apposite Capital LLP, SR One, Merck Serono, and Aravis SA.

For more information please visit www.anaphore.com.Media Contact:Heidi Chokeir, Ph.D.Russo Partners, LLC858-380-6584heidi.chokeir@russopartnersllc.com
'/>"/>

SOURCE Anaphore Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders
2. Cancer Treatment Centers Oncology Information System Options Expand with New MOSAIQ Connectivity
3. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
4. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
5. Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
6. Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited
7. CURE Foundation Selects Varian Medical Systems to Supply Radiotherapy Technology for Five New Cancer Centers
8. Merlot OrthopediX Enters into Exclusive Global Agreement with Alphatec Spine to Develop and Market Merlots Bone Anchorage Technology for the Treatment of Spine Disorders
9. HealthSport Enters Letter of Intent With CURE Pharmaceutical for Joint Development of Unique Pediatric Malaria Drug Product and Other Healthcare Related Products
10. Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
11. Fenwal Named Exclusive Provider of AccuVeins Award-Winning Vein Illumination Device for Blood and Plasma Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)...   Bernstein Liebhard LLP today announced that a ... District Court for the District of Arizona ... all persons or entities who purchased common shares of Insys ... from March 3, 2015 through January 25, 2016 (the "Class ... with violations of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... 2016  Montoya Love is recognized by Continental Who,s ... Pharmaceuticals. Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range ... provides healthcare institutions, clinical laboratories and life science researchers ... the globe. ...
(Date:2/4/2016)... -- Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) ... Chronic Obstructive Pulmonary Disease (COPD) is a ... airways and lungs. Persistent breathing difficulties and repeated ... of the leading causes of morbidity and the ... is linked to cumulative exposure to risk factors, ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with ... time to make a change in public health,” states Carole Baggerly, Director of ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering ... 2016 in honor of his birthday on February 10th. During this time, people ... is known by over 250,000 people from over 40 different countries as an “ordinary ...
(Date:2/7/2016)... Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... recognition of National Wear Red Day. National Wear Red Day is the first ... in women. Heart disease and stroke cause 1 in 3 deaths among women each ...
(Date:2/6/2016)... ... 06, 2016 , ... US Sports Camps is proud to sponsor the Bay ... together top non-profit leaders, ultimate organizations, and coaches from around the US. The theme ... Disc Program Director of Youth and Education, describes this year YUCC as “an important ...
(Date:2/5/2016)... SARASOTA, Florida (PRWEB) , ... February 05, 2016 , ... ... an event he has completed every year since it started in 2003. This year, ... attracting the attention of fellow runners and NBA team the Miami Heat. , This ...
Breaking Medicine News(10 mins):